JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

Search

Alkermes PLC

Open

SectorHealthcare

30.16 -3.86

Overview

Share price change

24h

Current

Min

29.88

Max

31.32

Key metrics

By Trading Economics

Income

65M

87M

Sales

84M

391M

P/E

Sector Avg

14.613

37.461

Profit margin

22.295

Employees

1,800

EBITDA

99M

113M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+29.09% upside

Dividends

By Dow Jones

Next Earnings

28 paź 2025

Market Stats

By TradingEconomics

Market Cap

802M

5.1B

Previous open

34.02

Previous close

30.16

News Sentiment

By Acuity

50%

50%

168 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 paź 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 paź 2025, 22:13 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 paź 2025, 21:20 UTC

Earnings

Correction to IBM 3Q Sales Jump Article

22 paź 2025, 20:57 UTC

Earnings

SAP Posts Higher 3Q Revenue, Operating Profit

22 paź 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 paź 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 paź 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 paź 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 paź 2025, 23:15 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 paź 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 paź 2025, 22:02 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 paź 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 paź 2025, 21:58 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 paź 2025, 21:57 UTC

Acquisitions, Mergers, Takeovers

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 paź 2025, 21:56 UTC

Acquisitions, Mergers, Takeovers

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 paź 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 paź 2025, 21:47 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 paź 2025, 21:47 UTC

Acquisitions, Mergers, Takeovers

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 paź 2025, 21:46 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 paź 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 paź 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 paź 2025, 21:28 UTC

Market Talk
Earnings

Correction to Alcoa Tariff Market Talk

22 paź 2025, 21:25 UTC

Earnings

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 paź 2025, 21:17 UTC

Earnings

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 paź 2025, 21:09 UTC

Market Talk
Earnings

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 paź 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22 paź 2025, 20:59 UTC

Earnings

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 paź 2025, 20:51 UTC

Earnings

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 paź 2025, 20:44 UTC

Earnings

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

29.09% upside

12 Months Forecast

Average 40.6 USD  29.09%

High 47 USD

Low 33 USD

Based on 11 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

27.95 / 30.91Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

168 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat